CPRX Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 17.96%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 50.9%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.05 which suggests that it could grow by 4.09%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Bristol Myers Squibb Co..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.87% to investors and pays a quarterly dividend of $0.62 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.48x while Bristol Myers Squibb Co.'s PE ratio is 17.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.07x versus 2.16x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Collegium Pharmaceutical, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 15.05%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Collegium Pharmaceutical, Inc.'s return on equity of 24.26%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 50.9%. On the other hand Collegium Pharmaceutical, Inc. has an analysts' consensus of $46.80 which suggests that it could fall by -2.19%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Collegium Pharmaceutical, Inc. has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Collegium Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Collegium Pharmaceutical, Inc. quarterly revenues of $209.4M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is higher than Collegium Pharmaceutical, Inc.'s net income of $31.5M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.48x while Collegium Pharmaceutical, Inc.'s PE ratio is 29.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.07x versus 2.39x for Collegium Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 10.24%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 50.9%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.90 which suggests that it could grow by 62.58%. Given that Amicus Therapeutics, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.48x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.07x versus 5.00x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 30.04%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Zoetis, Inc.'s return on equity of 52.95%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 50.9%. On the other hand Zoetis, Inc. has an analysts' consensus of $165.36 which suggests that it could grow by 37.03%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Zoetis, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Zoetis, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.841%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.63% to investors and pays a quarterly dividend of $0.50 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is lower than Zoetis, Inc.'s net income of $721M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.48x while Zoetis, Inc.'s PE ratio is 20.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.07x versus 5.83x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.